Inorder to overcome these drawbacks, several biomarkers have been evaluated for theearly diagnosis and AKI risk stratification, as the combination of Interleukin-18(IL-18) and Kidney Injury Molecule 1 (KIM-1)4. This evidence concerns the gene HAVCR1 and acute kidney injury.